Tagged with Global

Saudi Arabia Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease.   As people live longer, the threat of age-related diseases deepens. Alzheimer’s, one of the cruellest such diseases, therefore represents an increasingly urgent public health challenge in…

Saudi Arabia Saudi Arabia is rapidly shaping its future as a global research powerhouse, channelling unprecedented resources into translational research, clinical trials, and genomics. At the heart of this transformation is the Saudi NIH, driving 13 key research priorities and forging strategic global partnerships. Speaking at The Global Healthspan Summit (GHS 2025)…

Saudi Arabia Despite groundbreaking advances in longevity science, one fundamental challenge remains: how to turn wellness into a scalable, investable industry. Speaking at The Global Healthspan Summit (GHS 2025) in Riyadh, Dr. Mehmood Khan, CEO of the Hevolution Foundation, argues that without a structured economic model, healthy longevity will remain an untapped…

Global HEOR is transforming healthcare decision-making by evaluating treatment costs, patient quality of life, and overall value, helping stakeholders make informed choices. ISPOR’s new “HEOR Explained” website simplifies these complex concepts to promote wider understanding and application of real-world evidence and ultimately drive more effective and sustainable healthcare.   In today’s…

Global A wave of blockbuster biologics is set to lose patent protection, creating a major inflection point for the biosimilars market in 2025 and beyond. While Europe remains the global leader in biosimilar adoption, South Korea is rapidly emerging as a powerhouse, leveraging strong government support and industry investment. However, a…

Japan After 12 years at the helm, Takeda CEO Christophe Weber is stepping down, leaving behind a transformed company. Under his leadership, Japan’s biggest drugmaker expanded globally with the $62 billion acquisition of Shire, made waves with its dengue vaccine QDENGA, navigated the loss of exclusivity on its ADHD blockbuster, and…

Global The 2025 Davos World Economic Forum brought together business leaders from multiple industries to debate the challenges and issues facing the world today. The Pharma CEOs in attendance discussed critical topics such as the impact of climate change on health, AI-driven innovation, and the complexities of global trade tensions, all…

Global In an era of rapid scientific breakthroughs, global regulators are navigating new challenges—accelerating approvals, harmonising standards, and integrating digital tools—while balancing safety, efficacy, and access. Throughout 2024, PharmaBoardroom spoke with regulators worldwide to uncover the key regulatory trends shaping the future of healthcare in 2025 and beyond.   The Road…

Global While many diagnostics companies have suffered from the decline in COVID-19 testing since the pandemic, the sector, expected to grow from USD 210.58 billion to reach USD 284.38 billion by 2033, continues to thrive as it brings forward new levels of innovation and precision for a range of diseases. We…

Global Regular PharmaBoardroom contributor David H. Crean outlines the resilient and cautious optimism observed at JPM 2025, the annual healthcare financing conference held near San Francisco’s Union Square. While uncertainties and headwinds still persist, particularly around regulatory changes, affordability issues, and capital financing in the public and private markets, the healthcare…

Global Drawing on insights from DIA’s 2024 Global Annual Meeting, Martin Hodosi and Rosanna Lim of Kearney Healthcare and Life Sciences examine some of the key ethical challenges around integrating AI into healthcare.   Artificial intelligence (AI) has already begun transforming the healthcare industry, with applications ranging from diagnostics to drug…

Global In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain their CEOs, focusing instead on reshaping management at other levels. Companies like Bayer underwent sweeping transformations, while others, such as…